Skip to main content

Moberg Pharma expands Domeboro® retail presence with Walmart launch

STOCKHOLM, March 4, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that it will ship opening orders of its first aid product Domeboro® in over 3,500 Walmart stores within the next week. 

Domeboro®, a topical astringent used for relieving itch and minor skin irritations will be available in Walmart ahead of the spring season.  Trusted by healthcare professionals and consumers for over 50 years, Domeboro is a highly effective treatment for skin irritations due to poison ivy, oak, sumac and rashes.   Domeboro will be sold in approximately 3,500 Walmart locations across the U.S. Domeboro is already listed in several leading retailers including Walgreens, CVS and Rite Aid. Visit for more information. 

“We are excited to add Walmart to the list of major U.S. retailers who already stock Domeboro and particularly pleased to gain distribution in advance of the spring season.  Currently snow is blanketing much of the country, but we know warm weather will soon be here as will the inevitable skin rashes caused by poison ivy and other irritants”, said Jeff Vernimb, General Manager of Moberg Pharma North America, and he continues; ”Since Domeboro is a strategic brand for Moberg Pharma, expanding the distribution with Walmart is a high priority which will contribute to sales and earnings in 2015”.

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®as well as Phase II pipeline assets. Kerasal Nail® (Emtrix® and Nalox™ in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: